Get the Stockscreener App
22.75
2.49%
-0.58
After Hours:
23.63
0.88
+3.87%
Viridian Therapeutics Inc stock is traded at $22.75, with a volume of 864.58K.
It is down -2.49% in the last 24 hours and up +54.97% over the past month.
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate VRDN-001 is an insulin-like growth factor-1 receptor (IGF-1R) monoclonal antibody (mAb) being developed for the potential treatment for patients with thyroid eye disease.
See More
Previous Close:
$23.33
Open:
$22.75
24h Volume:
864.58K
Relative Volume:
0.59
Market Cap:
$1.77B
Revenue:
$314.00K
Net Income/Loss:
$-237.73M
P/E Ratio:
-4.6715
EPS:
-4.87
Net Cash Flow:
$-185.07M
1W Performance:
+7.72%
1M Performance:
+54.97%
6M Performance:
+29.93%
1Y Performance:
+48.31%
1-Day Range:
$22.14
$23.53
1-Week Range:
$20.37
$23.76
52-Week Range:
$10.93
$24.18
Viridian Therapeutics Inc Stock (VRDN) Company Profile
Name
Viridian Therapeutics Inc
Sector
Industry
Phone
617.272.4600
Address
221 CRESCENT STREET, WALTHAM
Viridian Therapeutics Inc Stock (VRDN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-14-23 | Initiated | BTIG Research | Buy |
| Jun-14-23 | Resumed | Credit Suisse | Outperform |
| May-30-23 | Initiated | RBC Capital Mkts | Outperform |
| Apr-17-23 | Initiated | Wells Fargo | Overweight |
| Mar-30-23 | Initiated | Stifel | Buy |
| Dec-19-22 | Initiated | Cowen | Outperform |
| Dec-19-22 | Initiated | Needham | Buy |
| Dec-16-22 | Initiated | Credit Suisse | Outperform |
| Dec-01-22 | Initiated | H.C. Wainwright | Buy |
| Jun-23-22 | Initiated | B. Riley Securities | Buy |
| Nov-18-21 | Initiated | SVB Leerink | Outperform |
| Oct-12-21 | Initiated | Evercore ISI | Outperform |
| Jan-25-21 | Initiated | Ladenburg Thalmann | Buy |
View All
Viridian Therapeutics Inc Stock (VRDN) Latest News
Viridian Therapeutics COO buys $117k in company stock - Investing.com
Viridian Therapeutics CEO buys $499k worth of company stock - Investing.com
Viridian Therapeutics' SWOT analysis: biotech stock poised for growth in TED market - Investing.com Canada
Viridian Therapeutics' SWOT analysis: biotech stock poised for growth in TED market - Investing.com India
Perceptive Advisors LLC Trims Holdings in Viridian Therapeutics, Inc. (NASDAQ:VRDN) - MarketBeat
Viridian Therapeutics' SWOT analysis: biotech stock poised for growth in TED market - Investing.com
Short Interest in Viridian Therapeutics, Inc. (NASDAQ:VRDN) Increases By 30.3% - MarketBeat
Maverick Capital Ltd. Buys 615,531 Shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN) - MarketBeat
Forecasting The Future: 13 Analyst Projections For Viridian Therapeutics - Benzinga
Viridian Therapeutics, Inc. (NASDAQ:VRDN) Receives $35.30 Average PT from Brokerages - MarketBeat
Viridian Therapeutics (NASDAQ:VRDN) Trading Up 2.3% - MarketBeat
Affinity Asset Advisors LLC Invests $1.95 Million in Viridian Therapeutics, Inc. (NASDAQ:VRDN) - MarketBeat
Great Point Partners LLC Sells 835,000 Shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN) - MarketBeat
Viridian Therapeutics (NASDAQ:VRDN) Trading Down 4.9% - MarketBeat
Viridian (VRDN): A Biotech Targeting Rare Disease Growth - Value the Markets
Rhumbline Advisers Purchases 23,305 Shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN) - MarketBeat
Trading (VRDN) With Integrated Risk Controls - Stock Traders Daily
Viridian Therapeutics’ (VRDN) Outperform Rating Reaffirmed at Royal Bank of Canada - Defense World
Viridian Therapeutics’ $258.8 Million Follow-on Public Offering - Global Legal Chronicle
Royal Bank of Canada Reiterates Outperform Rating for Viridian Therapeutics (NASDAQ:VRDN) - MarketBeat
Viridian Therapeutics (NASDAQ:VRDN) Shares Gap Up After Insider Buying Activity - MarketBeat
It makes sense and dollars to buy Viridian Therapeutics Inc (VRDN) stock - SETE News
Bank of New York Mellon Corp Has $2.72 Million Position in Viridian Therapeutics, Inc. (NASDAQ:VRDN) - MarketBeat
WilmerHale Advises Underwriters in Upsized $258.8 Million Follow-on Public Offering of Viridian Therapeutics - WilmerHale
Brokers Set Expectations for Viridian Therapeutics, Inc.'s FY2024 Earnings (NASDAQ:VRDN) - MarketBeat
Viridian Therapeutics (NASDAQ:VRDN) Given New $44.00 Price Target at Royal Bank of Canada - MarketBeat
RBC raises Viridian Therapeutics shares price target, maintains Outperform rating - Investing.com UK
Viridian Therapeutics (NASDAQ:VRDN) Price Target Raised to $31.00 at The Goldman Sachs Group - MarketBeat
Viridian Therapeutics (NASDAQ:VRDN) Shares Up 4.8% on Analyst Upgrade - MarketBeat
Trend Tracker for (VRDN) - Stock Traders Daily
Viridian Therapeutics (NASDAQ:VRDN) Price Target Raised to $38.00 at Needham & Company LLC - Defense World
Viridian Therapeutics Announces Pricing of Upsized Public Offering of Shares of Common Stock and Preferred Stock - BioSpace
Viridian Therapeutics Announces Pricing of Upsized Public Offering of Shares of Common Stock and Preferred Stock - StockTitan
Viridian Therapeutics Says Selling 10.7 Mln Shares Of Common Stock At $18.75 Per Share - XM
Viridian Therapeutics Announces Pricing of Upsized Public Offering of Shares of Common Stock and Preferred Stock - Business Wire
Viridian Therapeutics launches $150 million public offering - Investing.com India
VRDN Stock Soars as Eye Disorder Study Meets Primary Endpoints - Nasdaq
Needham & Company LLC Increases Viridian Therapeutics (NASDAQ:VRDN) Price Target to $38.00 - MarketBeat
Viridian Therapeutics (NASDAQ:VRDN) Sees Unusually-High Trading Volume Following Analyst Upgrade - MarketBeat
B.Riley raises Viridian Therapeutics shares target on Phase III THRIVE study - Investing.com Canada
VRDN Stock Soars as Eye Disorder Study Meets Primary Endpoints - Zacks Investment Research
Needham raises Viridian stock price target, maintains Buy rating By Investing.com - Investing.com Canada
Viridian Therapeutics’ stock jumps after Phase III trial met all endpoints - Clinical Trials Arena
Is Viridian Therapeutics (NASDAQ:VRDN) Weighed On By Its Debt Load? - Simply Wall St
Viridian Therapeutics (NASDAQ:VRDN) Price Target Raised to $56.00 at BTIG Research - Defense World
Viridian Therapeutics’ stock jumps after Phase III trial met all endpoints - Yahoo Finance
Viridian Therapeutics reports positive results for veligrotug - The Pharma Letter
Viridian Therapeutics (NASDAQ:VRDN) Given Buy Rating at HC Wainwright - Defense World
Viridian Therapeutics Announces Proposed Underwritten Public Offering of Common Stock and Preferred Stock - BioSpace
After-hours movers: GameStop, Dave & Buster's, Viridian Therapeutics By Investing.com - Investing.com Canada
Viridian’s Veligrotug Poses Formidable Challenge For Amgen’s Tepezza In TED - Scrip
Viridian Therapeutics Inc Stock (VRDN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.05%
4.86%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):